🔗 Share this article

Given that the United States undertakes sweeping changes to its vaccination schedules, a particular individual appears unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by expressing skepticism about COVID-19 shots during the global health crisis and has focused upon alleged deaths following Covid vaccination in her short time at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Vaccine Schedule

Public health authorities planned to announce major changes to the childhood vaccine schedule recently, aligning the US with the Danish vaccine program, it is understood – a substantial departure that would put the US at odds with many the global community with insufficient data for improved outcomes. The planned update has been delayed until the coming year.

Instead of Vinay Prasad, Høeg is listed to address the audience at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the center this year.

A New Direction at the Agency

Høeg's temporary position could signify a tighter collaboration between the drug and biologics branches as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a increased emphasis upon rolling back previously authorized vaccines at the FDA.

The new acting director has frequently advocated for ending certain pediatric vaccine recommendations in the US in order to be more similar to the Danish model, a society with nationalized medicine and a citizenry approximately the population of the state of Wisconsin.

So far comments, she has kept her attention on vaccination policy – typically the responsibility of Dr. Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Background

The appointee has little discernible background in pharmaceutical research, approval processes or leadership, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and CBER since March.

“She doesn’t seem to have the requisite experience” for overseeing the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in managing a large organization. She has no expertise in pharmaceutical oversight.”

Past commissioners of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of medication creation”, said Janet Woodcock. “Objectively, she has not acquired the sort of resume that previous people who led CBER have had.”

CDER has an enormous workload at the agency, Woodcock emphasized.

“Everybody just zeroes in on the novel medication approvals, but the generic program approves thousands of generic drugs. There’s a biosimilars division, OTC medication office and so forth, and every single one need to be managed,” Dr. Woodcock noted. “The responsibility you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a major administrative component to the position, which manages more than 5,000 personnel. “It’s a massive administrative position, if you do it right,” the former official concluded.

Agency Reaction and Contentious Policies

When asked about concerns about Dr. Høeg's fitness for the role and whether this assignment signifies greater collaboration among agency officials on vaccines, a representative responded that the “inquiries are based on inaccurate assumptions”.

“This background aligns with the functions of her position,” the spokesperson stated, pointing to the time Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

As acting director, Høeg takes over the agency head's new priority voucher program, a disputed one-day therapy clearance system that reportedly worried her former heads. “By what process are these drugs being selected for this voucher program? Who makes the choices?” Dr. Howard said. “There’s a lot of secrecy happening at the FDA right now.”

In general, he remarked, “the FDA looks to be trending towards more relaxed rules of all drugs, aside from shots.”

Documented History on Immunizations

With vaccines, Dr. Høeg has a more established, if problematic, past, Howard have noted. She published a research paper using unconfirmed crowd-sourced reports to determine the rate of heart inflammation following Covid immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Part of her “policy goals” for the current administration featured revising guidelines for new vaccines and discontinuing “unnecessary” immunizations, she remarked after the election on a audio program. At the agency, Dr. Høeg has allegedly proposed barring young men from obtaining COVID-19 vaccinations.

“She’s an complete ideologue who commences with her conclusions and works backwards to retrofit the evidence in a highly disingenuous, fraudulent fashion,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with fellow dissenters, {like|